Ablynx NV - Product Pipeline Review - 2016

  • ID: 3766776
  • Company Profile
  • 57 pages
  • Global Markets Direct
  • Ablynx
1 of 4
Ablynx NV - Product Pipeline Review - 2016

Summary

The report ‘Ablynx NV - Product Pipeline Review - 2016’, provides an overview of the Ablynx NV’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ablynx NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Ablynx NV
- The report provides overview of Ablynx NV including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ablynx NV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ablynx NV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Ablynx NV’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ablynx NV
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ablynx NV’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Ablynx NV Snapshot

Ablynx NV Overview

Key Information

Key Facts

Ablynx NV - Research and Development Overview

Key Therapeutic Areas

Ablynx NV - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Ablynx NV - Pipeline Products Glance

Ablynx NV - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Ablynx NV - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Ablynx NV - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Ablynx NV - Drug Profiles

caplacizumab

Product Description

Mechanism of Action

R&D Progress

ALX-0061

Product Description

Mechanism of Action

R&D Progress

ozoralizumab

Product Description

Mechanism of Action

R&D Progress

ALX-0171

Product Description

Mechanism of Action

R&D Progress

ALX-0141

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Immunology and Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Inflammation and Osteoarthritis

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Multiple Sclerosis

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Target c-Met for Multiple Myeloma

Product Description

Mechanism of Action

R&D Progress

TLC-520

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Agonize GITR for Immunology and Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 1 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 2 for Oncology

Product Description

Mechanism of Action

R&D Progress

Ablynx NV - Pipeline Analysis

Ablynx NV - Pipeline Products by Target

Ablynx NV - Pipeline Products by Route of Administration

Ablynx NV - Pipeline Products by Molecule Type

Ablynx NV - Pipeline Products by Mechanism of Action

Ablynx NV - Recent Pipeline Updates

Ablynx NV - Dormant Projects

Ablynx NV - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

BI-1034020

Ablynx NV - Company Statement

Ablynx NV - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Ablynx NV, Key Information

Ablynx NV, Key Facts

Ablynx NV - Pipeline by Indication, 2016

Ablynx NV - Pipeline by Stage of Development, 2016

Ablynx NV - Monotherapy Products in Pipeline, 2016

Ablynx NV - Partnered Products in Pipeline, 2016

Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2016

Ablynx NV - Out-Licensed Products in Pipeline, 2016

Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2016

Ablynx NV - Phase III, 2016

Ablynx NV - Phase II, 2016

Ablynx NV - Phase I, 2016

Ablynx NV - Preclinical, 2016

Ablynx NV - Discovery, 2016

Ablynx NV - Pipeline by Target, 2016

Ablynx NV - Pipeline by Route of Administration, 2016

Ablynx NV - Pipeline by Molecule Type, 2016

Ablynx NV - Pipeline Products by Mechanism of Action, 2016

Ablynx NV - Recent Pipeline Updates, 2016

Ablynx NV - Dormant Developmental Projects,2016

Ablynx NV - Discontinued Pipeline Products, 2016

Ablynx NV, Subsidiaries

List of Figures

Ablynx NV - Pipeline by Top 10 Indication, 2016

Ablynx NV - Pipeline by Stage of Development, 2016

Ablynx NV - Monotherapy Products in Pipeline, 2016

Ablynx NV - Partnered Products in Pipeline, 2016

Ablynx NV - Out-Licensed Products in Pipeline, 2016

Ablynx NV - Pipeline by Target, 2016

Ablynx NV - Pipeline by Route of Administration, 2016

Ablynx NV - Pipeline by Molecule Type, 2016

Ablynx NV - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll